- United Therapeutics (UTHR -4.4%) goes south on modestly higher volume on the heels of an Underperform rating and $120 (14% downside risk) price target by Credit Suisse.
- Analyst Alethia Young cites valuation and potential negative catalysts including a potential invalidity decision on its '393 patent (being challenged by SteadyMed) and a delay of RemoSynch approval due to the possible delay in the approval of the Medtronic device that will be used in the product.
- Source: Bloomberg
Credit Suisse negative on United Therapeutics; shares slip 4%
Recommended For You
About UTHR Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| UTHR | - | - |
| United Therapeutics Corporation | ||